✦ LIBER ✦

Salvage therapy with single agent bevacizumab for recurrent glioblastoma

✍ Scribed by Marc C. Chamberlain; Sandra K. Johnston

Publisher: Springer US
Year: 2009
Tongue: English
Weight: 225 KB
Volume: 96
Category: Article
ISSN: 0167-594X
DOI: 10.1007/s11060-009-9957-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Salvage therapy with single agent bendam

Salvage therapy with single agent bendamustine for recurrent glioblastoma

✍ Marc C. Chamberlain; Sandra K. Johnston 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 229 KB

Recurrent spinal cord glioblastoma: salv

Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab

✍ Marc C. Chamberlain; Sandra K. Johnston 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 192 KB

Phase II study of metronomic chemotherap

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

✍ David A. Reardon; Annick Desjardins; Katherine Peters; Sridharan Gururangan; Joh 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 230 KB

Salvage chemotherapy with bevacizumab fo

Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma

✍ Marc C. Chamberlain; Sandra Johnston 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 207 KB

Phase 2 study of carboplatin, irinotecan

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

✍ David A. Reardon; Annick Desjardins; Katherine B. Peters; James J. Vredenburgh; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB

Salvage chemotherapy with cyclophosphami

Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme

✍ Marc C. Chamberlain; Denice D. Tsao-Wei 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

## Abstract ## BACKGROUND The primary objective of the current prospective Phase II study of cyclophosphamide (CYC) in adult patients with recurrent, temozolomide‐refractory glioblastoma multiforme was to evaluate 6‐month progression‐free survival (PFS). ## METHODS Forty patients (28 men and 12